Evans Jason Eric 4

What Happened

• Jason Evans, CEO of Surgery Partners (SGRY), was granted two restricted stock awards (RSAs) on March 5, 2026 totaling 278,106 shares valued at about $3.92 million. The grants reported were 141,743 shares at $14.11 ($1,999,994) and 136,363 shares at $14.11 ($1,924,082). Separately, on March 6, 2026 Evans sold 11,462 shares in an open-market/private sale at a weighted average price of $13.79 for proceeds of $158,061; the sale was to satisfy tax withholding obligations related to prior vesting.

Key Details

• Transaction types: A = Award/Grant (two RSAs on 2026-03-05); S = Sale (11,462 shares on 2026-03-06).
• Prices and amounts: Grants — 141,743 @ $14.11 ($1,999,994) and 136,363 @ $14.11 ($1,924,082); Sale — 11,462 @ $13.79 ($158,061, weighted average).
• Vesting: One RSA (141,743 shares) vests in three equal annual installments beginning on the first anniversary of the March 5, 2026 grant; the other RSA (136,363 shares) vests in full on the first anniversary (per footnotes).
• Sale reason: Footnote indicates shares were sold to satisfy the reporting person’s tax withholding obligations tied to restricted stock vesting (routine tax-withholding sale).
• Price reporting: The sale price is a weighted average; full per-share breakdown can be provided on request (footnote).
• Filing timeliness: Form 4 was filed March 9, 2026; based on the March 5–6 transactions this filing date is within the typical 2-business-day reporting window.

Context

• These were equity awards (not open-market purchases); awards do not reflect an immediate cash outlay by the insider and will only convert to freely tradable shares as they vest. The small sale was a routine tax-withholding sale rather than an expression of market sentiment.